EFFECTS OF PROSOMATOSTATIN ON GROWTH HORMONE AND PROLACTIN RESPONSE TO ARGININE IN MAN Comparison with Somatostatin

M. D. Rodriguez-Arnao, S. J. Rainbow, A. M. Comaru-Schally, C. A. Meyers, A. Gomez-Pan, S. Woodhead, Andrew V Schally, D. H. Coy, R. Hall

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

The effects of the hypothalamic 28 aminoacid peptide prosomatostatin (Pro-SS) on arginine-induced growth hormone (GH) and prolactin (PRL) release and blood glucose levels in man are compared with those obtained after an equimolar dose of somatostatin (SS). In comparison with SS, Pro-SS caused greater and more prolonged inhibition of GH release, a more marked reduction of the PRL response to arginine, and greater enhancement of the hyperglycaemic action of arginine. The greater potency and prolonged action of Pro-SS make it an interesting tool to study hormonal control mechanisms in a variety of physiological and pathological conditions.

Original languageEnglish
Pages (from-to)353-356
Number of pages4
JournalThe Lancet
Volume317
Issue number8216
DOIs
StatePublished - Feb 14 1981
Externally publishedYes

Fingerprint

Somatostatin
Prolactin
Growth Hormone
Arginine
Blood Glucose
Peptides
prosomatostatin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Rodriguez-Arnao, M. D., Rainbow, S. J., Comaru-Schally, A. M., Meyers, C. A., Gomez-Pan, A., Woodhead, S., ... Hall, R. (1981). EFFECTS OF PROSOMATOSTATIN ON GROWTH HORMONE AND PROLACTIN RESPONSE TO ARGININE IN MAN Comparison with Somatostatin. The Lancet, 317(8216), 353-356. https://doi.org/10.1016/S0140-6736(81)91673-1

EFFECTS OF PROSOMATOSTATIN ON GROWTH HORMONE AND PROLACTIN RESPONSE TO ARGININE IN MAN Comparison with Somatostatin. / Rodriguez-Arnao, M. D.; Rainbow, S. J.; Comaru-Schally, A. M.; Meyers, C. A.; Gomez-Pan, A.; Woodhead, S.; Schally, Andrew V; Coy, D. H.; Hall, R.

In: The Lancet, Vol. 317, No. 8216, 14.02.1981, p. 353-356.

Research output: Contribution to journalArticle

Rodriguez-Arnao, MD, Rainbow, SJ, Comaru-Schally, AM, Meyers, CA, Gomez-Pan, A, Woodhead, S, Schally, AV, Coy, DH & Hall, R 1981, 'EFFECTS OF PROSOMATOSTATIN ON GROWTH HORMONE AND PROLACTIN RESPONSE TO ARGININE IN MAN Comparison with Somatostatin', The Lancet, vol. 317, no. 8216, pp. 353-356. https://doi.org/10.1016/S0140-6736(81)91673-1
Rodriguez-Arnao MD, Rainbow SJ, Comaru-Schally AM, Meyers CA, Gomez-Pan A, Woodhead S et al. EFFECTS OF PROSOMATOSTATIN ON GROWTH HORMONE AND PROLACTIN RESPONSE TO ARGININE IN MAN Comparison with Somatostatin. The Lancet. 1981 Feb 14;317(8216):353-356. https://doi.org/10.1016/S0140-6736(81)91673-1
Rodriguez-Arnao, M. D. ; Rainbow, S. J. ; Comaru-Schally, A. M. ; Meyers, C. A. ; Gomez-Pan, A. ; Woodhead, S. ; Schally, Andrew V ; Coy, D. H. ; Hall, R. / EFFECTS OF PROSOMATOSTATIN ON GROWTH HORMONE AND PROLACTIN RESPONSE TO ARGININE IN MAN Comparison with Somatostatin. In: The Lancet. 1981 ; Vol. 317, No. 8216. pp. 353-356.
@article{ef9f1382334149f0ac6c9ef2c90cb02b,
title = "EFFECTS OF PROSOMATOSTATIN ON GROWTH HORMONE AND PROLACTIN RESPONSE TO ARGININE IN MAN Comparison with Somatostatin",
abstract = "The effects of the hypothalamic 28 aminoacid peptide prosomatostatin (Pro-SS) on arginine-induced growth hormone (GH) and prolactin (PRL) release and blood glucose levels in man are compared with those obtained after an equimolar dose of somatostatin (SS). In comparison with SS, Pro-SS caused greater and more prolonged inhibition of GH release, a more marked reduction of the PRL response to arginine, and greater enhancement of the hyperglycaemic action of arginine. The greater potency and prolonged action of Pro-SS make it an interesting tool to study hormonal control mechanisms in a variety of physiological and pathological conditions.",
author = "Rodriguez-Arnao, {M. D.} and Rainbow, {S. J.} and Comaru-Schally, {A. M.} and Meyers, {C. A.} and A. Gomez-Pan and S. Woodhead and Schally, {Andrew V} and Coy, {D. H.} and R. Hall",
year = "1981",
month = "2",
day = "14",
doi = "10.1016/S0140-6736(81)91673-1",
language = "English",
volume = "317",
pages = "353--356",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "8216",

}

TY - JOUR

T1 - EFFECTS OF PROSOMATOSTATIN ON GROWTH HORMONE AND PROLACTIN RESPONSE TO ARGININE IN MAN Comparison with Somatostatin

AU - Rodriguez-Arnao, M. D.

AU - Rainbow, S. J.

AU - Comaru-Schally, A. M.

AU - Meyers, C. A.

AU - Gomez-Pan, A.

AU - Woodhead, S.

AU - Schally, Andrew V

AU - Coy, D. H.

AU - Hall, R.

PY - 1981/2/14

Y1 - 1981/2/14

N2 - The effects of the hypothalamic 28 aminoacid peptide prosomatostatin (Pro-SS) on arginine-induced growth hormone (GH) and prolactin (PRL) release and blood glucose levels in man are compared with those obtained after an equimolar dose of somatostatin (SS). In comparison with SS, Pro-SS caused greater and more prolonged inhibition of GH release, a more marked reduction of the PRL response to arginine, and greater enhancement of the hyperglycaemic action of arginine. The greater potency and prolonged action of Pro-SS make it an interesting tool to study hormonal control mechanisms in a variety of physiological and pathological conditions.

AB - The effects of the hypothalamic 28 aminoacid peptide prosomatostatin (Pro-SS) on arginine-induced growth hormone (GH) and prolactin (PRL) release and blood glucose levels in man are compared with those obtained after an equimolar dose of somatostatin (SS). In comparison with SS, Pro-SS caused greater and more prolonged inhibition of GH release, a more marked reduction of the PRL response to arginine, and greater enhancement of the hyperglycaemic action of arginine. The greater potency and prolonged action of Pro-SS make it an interesting tool to study hormonal control mechanisms in a variety of physiological and pathological conditions.

UR - http://www.scopus.com/inward/record.url?scp=0019379323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019379323&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(81)91673-1

DO - 10.1016/S0140-6736(81)91673-1

M3 - Article

VL - 317

SP - 353

EP - 356

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8216

ER -